Department of Neurology, Tufts University School of Medicine, Lahey Clinic, Burlington, MA 01805, USA.
Clin Interv Aging. 2010 May 25;5:149-56. doi: 10.2147/cia.s4145.
Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting 1% to 2% of people older than 60 years. Treatment of PD consists of symptomatic therapies while neuroprotective strategies have remained elusive. Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of PD. Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. In several large, randomized, placebo-controlled trials, rasagiline has demonstrated efficacy as monotherapy in early PD and as adjunctive therapy in advanced PD. In addition, rasagiline has been shown to have neuroprotective effects in in vitro and in vivo studies. The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established.
帕金森病（PD）是第二常见的神经退行性疾病，影响 60 岁以上人群的 1%至 2%。PD 的治疗包括对症治疗，而神经保护策略仍然难以捉摸。雷沙吉兰是一种新型、强效、不可逆的单胺氧化酶 B 型（MAO-B）抑制剂，已被批准用于治疗 PD。雷沙吉兰对 MAO-B 的抑制作用比司来吉兰更强，并且具有每日一次给药的优势。在几项大型、随机、安慰剂对照试验中，雷沙吉兰已被证明在早期 PD 中单药治疗有效，在晚期 PD 中作为辅助治疗有效。此外，雷沙吉兰在体外和体内研究中显示出神经保护作用。最近完成的延迟启动 ADAGIO（每日一次给予雷沙吉兰可减缓疾病进展）试验表明，雷沙吉兰 1mg/天可能具有潜在的疾病修饰作用，尽管这一发现的临床意义尚未确定。
